Takeda Files 6-K Report for May 2025
Ticker: TKPHF · Form: 6-K · Filed: May 14, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | May 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
TL;DR
Takeda filed its monthly 6-K, confirming 20-F filings and reporting from Tokyo.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on May 14, 2025, reporting information as a foreign private issuer. The filing is for the month of May 2025 and confirms Takeda's submission of annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.
Why It Matters
This filing provides routine updates for Takeda Pharmaceutical as a foreign private issuer, ensuring compliance with SEC reporting requirements.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- TAKEDA PHARMACEUTICAL CO LTD (company) — Filer
- 0001395064-25-000060 (accession_number) — Filing identifier
- 001-38757 (sec_file_number) — SEC filing number
- 20250514 (date) — Filing date
- Tokyo, Japan (location) — Principal executive offices
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the filer?
The filer is TAKEDA PHARMACEUTICAL CO LTD.
When was this form filed?
The form was filed on May 14, 2025.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan.
Does Takeda file annual reports under Form 20-F or 40-F?
Takeda indicates that it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 14, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).